Sec. K-5. 22 MRSA §3173-C, sub-§1, as amended by PL 1993, c. 6, Pt. C, §5, is further amended to read:

1. Authorization required. The department may not require any Medicaid recipient MaineCare member to make any payment toward the cost of a Medicaid MaineCare service unless that payment is specifically authorized by this section, except that any copayment or premium expressly approved by the federal Secretary of the Department of Health and Human Services as part of a waiver must be implemented.

Sec. K-6. 22 MRSA §3173-C, sub-§2, as amended by PL 1993, c. 6, Pt. C, §6, is further amended to read:

2. Prescription drug services. Except as provided in subsections 3 and 4, a payment of $2 $2.50 for generic drugs and $3 for brand-name drugs each drug is to be collected from the Medicaid recipient MaineCare member for each drug prescription that is an approved Medicaid MaineCare service. For the purposes of this section, a brand-name drug is defined as a single-source drug, a cross-licensed drug or an innovator drug for which a lower-cost generic equivalent is available. Copayments must be capped at $25 per month per member. If a recipient member is prescribed a drug in a quantity specifically intended by the provider or pharmacist, for the recipient's health and welfare, to last less than one month, only one payment for that drug for that month is required.

Sec. K-7. 22 MRSA §3173-C, sub-§7, ¶¶P and Q, as enacted by PL 1993, c. 410, Pt. I, §9, are amended to read:

P. Substance abuse services, $2; and

Q. Hospital inpatient services, $3 per patient day.;

Sec. K-8. 22 MRSA §3173-C, sub-§7, ¶¶R and S are enacted to read:

R.__Federally qualified health center services, $3 per patient day; and

S.__Rural health center services, $3 per patient day.

Sec. K-9. 22 MRSA §3173-F is enacted to read:

§3173-F.__Charging or increasing premiums